Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Therefore, beclabuvir represents a powerful weapon against HCV infection and has to be considered an optimal option in tailored IFN-free combinations. 26156630

2015

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE His serum hepatitis C virus (HCV) RNA level became undetectable 1 week after the initiation of peg-IFN-alpha2b plus ribavirin treatment. 17287904

2006

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE Our aim was to assess sustained virologic response (SVR)-associated early gene expression in patients with HCV receiving pegylated interferon-alpha2a (PEG-IFN-alpha2a) or PEG-IFN-alpha2b and ribavirin with the duration based on genotypes. 19140155

2009

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children. 25599750

2015

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE In conclusion, the Fib-4 score may predict early hematological adverse effects in HCV-infected patients on IFN-based triple therapy. 30657408

2019

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Two large clinical trials determined that each PEG-IFN alfa compound, when given in combination with ribavirin, results in overall sustained virological response (SVR) rates of approximately 50%; SVR rates in patients infected with hepatitis C virus (HCV) genotype 1 are typically lower (42-46%). 18363672

2008

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE These findings suggest that IFN-α can inhibit HCV replication through a STAT2-dependent but STAT1-independent pathway, whereas IFN-λ induces ISG expression and inhibits HCV replication exclusively through a STAT1- and STAT2-dependent pathway. 27929099

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Together, we conclude that serum apoB-100 concentrations could predict virological response to Peg-IFN plus RBV combination therapy in patients infected with HCV G1b, especially in those with the rs8099917 hetero/minor genotype. 23918536

2013

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE The relationship between virological relapse and the dose of PEG-IFNα-2b and RBV was investigated in 619 patients who had once cleared HCV RNA during PEG-IFNα-2b and RBV treatment for 48 weeks. 22450877

2012

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Quantification of viral genomes during acute and chronic HCV infection seem to be of major importance to predict the response rat to IFN. 8836886

1996

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE The analysis of the matched patient subgroup demonstrates that the HCV-5 "intrinsic sensitivity" to PEG-IFN + RBV therapy is identical to HCV-1, with a sustained virological response of 55% in both groups. 21412790

2011

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE These IFN-resistant HCVs were already present before therapy as minor quasispecies and were selected by IFN in nonresponders. 10479124

1999

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE In summary, intrahepatic expression of IFNL4 was associated with increased antiviral ISG expression and decreased suppressive ISG expression at baseline, resulting in poor responsiveness to IFNα-based therapy in HCV infection. 28036111

2017

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. 24927607

2015

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE We evaluated in this open-label, randomized controlled study the efficacy of fluvastatin as adjuvant to pegylated-(PEG)-IFN and ribavirin in HIV/HCV genotype 1 co-infected patients. 20118492

2010

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Evidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy. 26581744

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE DAA therapy causes far fewer adverse reactions compared with IFN therapy and has been reported to be highly effective in treating HCV infection in hemodialysis patients. 30041215

2018

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE To characterize the response of HCV-infected patients to treatment with IFNα, the expression of an IFN-response gene signature comprised of IFN-stimulated genes and genes that play an important role in the innate immune response was examined in liver biopsies from HCV-infected patients enrolled in a clinical trial. 25111807

2014

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Genome-wide transcriptional profiling was performed on peripheral blood mononuclear cells (PBMCs) from 21 patients with chronic hepatitis C virus (HCV) either awaiting IFN-α therapy (n=10) or at 12 weeks of IFN-α treatment (n=11). 22152193

2012

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Premature discontinuation due to the adverse effects of PEG-IFN α-2b and RBV treatment by patients with chronic HCV infection is mainly due to neuropsychiatric symptoms and is more common for older than for younger patients. 22098185

2012

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Early virological response rates to PEG-IFN plus RBV in HCV/HIV-coinfected patients seem to be similar to those reported for HCV-monoinfected subjects. 16152759

2005

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Interferon (IFN) lambda (IFN-λ or type III IFN) gene polymorphisms were discovered in the year 2009 to have a strong association with spontaneous and treatment-induced clearance of hepatitis C virus (HCV) infection in human hosts. 27278127

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Therefore, IFN-free anti-HCV treatment appears to be safe and effective in MC patients from virological and clinical points of view, thus supporting the importance of HCV eradication in leading MC remission. 26853322

2017

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Ribavirin is a weak antiviral but its clinical effect seems to be mediated by a separate, indirect mechanism, which may act to reset IFN-responsiveness in HCV-infected liver. 23396509

2014

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE HCV amino acid (aa) substitutions in non-structural protein 5a, including those in the IFN/RBV resistance-determining region (IRRDR) and the IFN sensitivity-determining region and the core regions, as well as the genetic variation (rs8099917) near the interleukin 28B (IL28B) gene (genotype TT) were analyzed. 22441534

2012